CD8A and central nervous system cancer: Our in vivo PET SUV results similarly indicated approximately twofold higher retention of the radiolabeled 169 cDb in intracranial glioma tumors treated with oHSV relative to non-treated or non-tumor control groups of mice, although our studies did not examine quantitative correlations between tumor infiltrating CD8+ cells and [89Zr]-malDFO-169 cDb retention as a function of oHSV treatment.